Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma

• DOI: 10.2147/ott.s404926
• Publication Date: 2023-04-10T06:10:08Z
• Authors: Yoichi Hamai; Manabu Emi; Yuta Ibuki; Tomoaki Kurokawa; Toru Yoshikawa; Manato Ohsawa; Ryosuke Hirohata; Nao Kitasaki; Morihito Okada
• Keywords: OncoTargets and Therapy; 3. Good health; Original Research

Various blood cell parameters have been identified as predictive markers of tumor responses and the survival patients with cancer treated immune checkpoint inhibitors. The purpose this study is to assess ability various predict therapeutic effects in esophageal squamous carcinoma (ESCC) nivolumab monotherapy.We evaluated neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR) lymphocyte-to-monocyte (LMR) ratios patients' monotherapy after one or more prior chemotherapies for unresectable advanced recurrent ESCC.The objective response disease control rates were 20.3% 47.5%, respectively. LMRs before, 14 28 days initiation significantly higher complete (CR)/partial (PR)/stable (SD) than those progressive (PD). NLRs at lower CR/PR/SD PD. optimal cutoffs these discriminated Univariate multivariate analyses pretreatment a significant independent factor progression-free overall (hazard ratio [HR]: 1.19, 95% confidence interval [CI]: 1.07-1.32, HR 1.23, CI: 1.11-1.37, respectively; p ≤ 0.001 both).The LMRs, NLR LMR starting associated clinical effect. was survival. These before during early can help identify ESCC who would most likely benefit from monotherapy.